logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Osteoporosis Steroidinduced

    Medications for Osteoporosis Steroidinduced

    FiltersReset Filters
    6 results

    • alendronate

      (ALENDRONATE SODIUM)
      Hangzhou Minsheng Binjiang Pharmaceutical Co., Ltd.
      Usage: Alendronate sodium tablets are indicated for treating and preventing osteoporosis in postmenopausal women, increasing bone mass in men with osteoporosis, treating glucocorticoid-induced osteoporosis, and treating Paget’s disease of bone. Use should be periodically re-evaluated, particularly for low-risk fracture patients after 3 to 5 years.

    • fosamax

      (alendronate sodium)
      Organon LLC
      Usage: FOSAMAX® is indicated for treating and preventing osteoporosis in postmenopausal women, increasing bone mass in men with osteoporosis, treating glucocorticoid-induced osteoporosis, and managing Paget's disease of bone in men and women. Treatment duration and reevaluation of therapy needs are recommended periodically.

    • prolia

      (denosumab)
      Amgen Inc
      Usage: Prolia is indicated for: treating osteoporosis in postmenopausal women and men at high fracture risk; glucocorticoid-induced osteoporosis; increasing bone mass in men undergoing androgen deprivation therapy for prostate cancer; and in women receiving aromatase inhibitor therapy for breast cancer. It reduces fracture incidence in these populations.

    • risedronate sodium

      (Risedronate Sodium)
      Greenstone LLC
      Usage: Risedronate Sodium is indicated for treating and preventing postmenopausal osteoporosis, increasing bone mass in men with osteoporosis, and preventing glucocorticoid-induced osteoporosis. It also treats Paget’s disease of bone in both men and women. Optimal duration of therapy has not been established, warranting periodic re-evaluation.

    • risedronate sodium

      (risedronate sodium)
      Sun Pharmaceutical Industries, Inc.
      Usage: Risedronate sodium is indicated for the treatment and prevention of postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis, and Paget's disease of bone. It reduces vertebral and nonvertebral osteoporosis-related fractures and helps increase bone mass in men. Regular re-evaluation of therapy is recommended.

    • risedronate sodium

      (Risedronate Sodium)
      Hangzhou Minsheng Binjiang Pharmaceutical CO., Ltd
      Usage: Risedronate sodium tablets are indicated for treating and preventing postmenopausal osteoporosis, increasing bone mass in men with osteoporosis, preventing osteoporosis induced by glucocorticoids, and treating Paget's disease. Regular assessment for continued therapy is necessary due to undetermined optimal duration of use.